...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Statistical Considerations
3
Mar 05, 2018 01:55PM
1
Mar 06, 2018 03:34AM
4
Mar 06, 2018 12:30PM
10
Mar 06, 2018 02:22PM
1
Mar 06, 2018 03:04PM

Mar 07, 2018 10:57AM
1
Mar 07, 2018 01:42PM
3
Mar 07, 2018 04:08PM
4
Mar 07, 2018 07:24PM
2
Mar 08, 2018 07:15AM
3
Mar 08, 2018 09:27AM
1
Mar 08, 2018 12:03PM
2
Mar 08, 2018 02:06PM

Mar 08, 2018 03:47PM

Mar 08, 2018 07:06PM
2
Mar 08, 2018 07:55PM

One of the links for the references in my last post was wrong. I corrected it here and added the hyperlinks.

Here's a few good resources on recent diabetes cardiovascular outcomes trials:

Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240079/

Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists—what will REWIND add?https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733310/

New Treatments for Type 2 Diabetes: Implications of Cardiovascular Outcome Trials (click here if the link below doesn't work) 

https://www.acponline.org/system/files/documents/about_acp/chapters/fl/17mtgs/pratley_new_treatments_for_type_2_diabetes.pdf

4
Mar 10, 2018 02:04PM
9
Mar 10, 2018 02:34PM
Share
New Message
Please login to post a reply